Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611290 | 1.00 | USP30 (0.42) | USP30GPR119STSARKLK7 | |
| SCHEMBL9611316 | 0.84 | GPR119 (0.40) | USP30GPR119ARTACR1NR1H2 | |
| SCHEMBL8510451 | 0.84 | GPR119 (0.40) | USP30GPR119ARTACR1NR1H2 | |
| SCHEMBL8350117 | 0.80 | CHRM2 (0.40) | ARNR1H2 | |
| SCHEMBL24111448 | 0.78 | USP30 (0.46) | USP30GPR119STSTACR1NR1H2 | |
| SCHEMBL26049974 | 0.78 | USP30 (0.46) | USP30GPR119STSTACR1NR1H2 | |
| SCHEMBL24111149 | 0.78 | USP30 (0.46) | USP30GPR119STSTACR1NR1H2 | |
| SCHEMBL9611358 | 0.76 | BACE1 (0.41) | GPR119KLK7TACR1 | |
| SCHEMBL2707640 | 0.76 | BACE1 (0.41) | GPR119KLK7TACR1 | |
| SCHEMBL4050279 | 0.75 | CHRM2 (0.42) | ARNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2434890-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | USP30 258/4885GPR119 163/4885STS 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.